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Abstract Most models of patient-physician communication take decision-making
as a central concept. However, we found that often the treatment course of metastatic
cancer patients is not easy to describe in straightforward terms used in decision-
making models but is instead frequently more erratic. Our aim was to analyse these
processes as trajectories. We used a longitudinal case study of 13 patients with
metastatic colorectal and pancreatic cancer for whom palliative chemotherapy was a
treatment option, and analysed 65 semi-structured interviews. We analysed three
characteristics of the treatment course that contributed to the ‘erraticness’ of the
course: (1) The treatment (with or without chemotherapy) contained many options;
(2)theseoptionswerenotstableentitiestobedecidedupon,butchangedidentityover
the course of treatment, and (3) contrary to the closure (option X means no option Y,
Z, etc.) a decision implies, the treatment course was a continuous process in which
options instead remained open. When the treatment course is characterised by these
manyandchangeableoptionsthatdonotresultinclosure,theshareddecision-making
model should take these into account. More attention needs to be paid to the erratic
character of the process in which the doctor has to provide continuous information
that is related to the changing situation of the patient; also, ﬂexibility in dealing with
protocols is warranted, as is vigilance about the overall direction of the process.
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Introduction
Different models of patient-physician communication exist. Paternalistic models, on
the one extreme, put the decision on the side of the physician, counselling models,
on the other, imply the picture of a patient making autonomous decisions on the
basis of proper information, and in-between, shared decision-making models view
making health care decisions as the common task of the physician and patient [2, 7].
However, the concept of decision-making plays a central role in these models. The
dictionary meaning of decision is: ‘a resolution or conclusion reached after
consideration’.
We investigated the process by which oncologists and patients shape the
treatment course in metastatic cancer. Decisions in the sense given above were often
hard to ﬁnd. Therefore, we question the idea that making a decision is the central
activity for understanding the course of treatment for metastatic cancer. Experi-
enced clinicians will not be surprised that in our study of the practise of metastatic
cancer treatment we found the treatment course to be quite erratic. Everyday
clinicians’ experience makes clear that the treatment course is indeed continually
being revised as the patient’s response, experience with treatment, and their disease
changes over time. However, not much is known about this process because, as far
as we know, it has not been investigated and articulated by empirical research
before. We will propose to call this process ‘shared trajectory making’.
We formulated the following research question: what characterises the course of
treatment for metastatic cancer that leads to starting, foregoing, continuing or
discontinuing, modifying, or switching palliative chemotherapy? To answer this
question, we observed outpatient physician-patient contacts and conducted
subsequent interviews with patients with metastatic colorectal and pancreatic
cancer for whom palliative chemotherapy was a treatment option, and single
interviews with their attending physicians and nurses.
On the basis of our results, we will suggest ways for improving the practise for
metastatic cancer patients.
Methods
We conducted a longitudinal case study of 13 patients with advanced pancreatic or
colorectal cancer from an outpatient medical oncology department at a university
teaching hospital in the Netherlands. Susanne de Kort (SdK) collected all the data.
We observed 60 outpatient physician-patient contacts in the practises of six medical
oncologists. During the research period, we also observed weekly team meetings in
which physicians and nurses discussed patients. The data from these observations
were used in the 30 single semi-structured interviews with the attending health care
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with patients. If there were no treatment changes, the interviews were held every
2 months for pancreatic cancer patients and every 3 months for colorectal cancer
patients. Between interviews, SdK stayed in contact by phone at least once a month.
A follow-up interview was planned if any changes in the disease course occurred.
A qualitative study design was used because we expected the process leading to a
certain treatment course (with or without chemotherapy) to be complex, and we
wanted to look for concepts without excluding variables in advance [1].
All patients gave informed consent prior to the start of the study, and during the
study the patients were repeatedly told it was possible to stop participating. Patients
were asked to give a separate consent to allow us to approach their general
practitioner for an interview. The Medical Ethics Committee of the Academic
Medical Center in Amsterdam granted a waiver for the study.
Sampling
Attending physicians included patients with incurable advanced pancreatic or
metastatic colorectal cancer (because of a different prognosis related to the chemo-
sensitivity of the tumours, which could inﬂuence the decision-making process) who
visited their outpatient medical oncology department. Patients with advanced
pancreatic cancer have a relatively poor prognosis with a mean survival time of
6 months; chemotherapy has virtually no effect on this [10].
Metastatic colorectal cancer is relatively chemo-sensitive: the prognosis has
improved from a mean survival time of 8 months (without treatment) to about
20 months (with a number of types of treatment) [14]. During weekly team
meetings, SdK coordinated the selection (purposive sampling) so that patients with
different ways of ‘deciding’ about the cancer treatment (‘‘long-lasting doubters’’,
‘‘refusers’’, and patients who were willing to have chemotherapy), and equal
distribution of cancer types, were included [16].
Between January 2004 and March 2004, 20 patients were selected in the weekly
team meetings. Three patients turned out to be ineligible due to a psychiatric
problem, an unconﬁrmed diagnosis, and refusal to cooperate. Four patients refused
because of the emotional character of the research subject. In the end, 13 patients
were included, and had the following characteristics:
• 7 had pancreatic cancer and 6 had colorectal cancer
• 3 were women and 10 were men
• they had an average age of 64 years (ranging from 41 to 82 years)
• 12 were Caucasian and 1 was Asian
• 4 had an university education and 9 did not
For the semi-structured interviews with health care professionals, we approached
different health care professionals who were or had been involved in the treatment
of our patient sample. With the exception of one general practitioner, all of them
agreed to an interview. Thus, 30 professionals were interviewed between June 2004
and October 2004: eight medical oncologists (two of whom were in training), eight
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specialised nurses.
The interviews with the nurses were performed by SdK and Dick Willems (DW)
in two focus groups [11]. These groups were organised according to the teams in
which they worked.
Interviews
A total of 35 semi-structured interviews were held: one patient was interviewed
once and two patients were interviewed twice (because they died before the second
and third interviews, respectively), and the other ten patients were interviewed three
times. In the ﬁrst interview, patients were asked about recent events related to their
cancer. Later on, questions focused more on the patients’ perceptions of and reasons
for certain treatments. The second and third interviews focused on new develop-
ments in the disease course, tried to reach a more comprehensive understanding of
the themes discussed in the previous interview(s), and discussed patients’ treatment
decisions. The patient interviews took place in their homes and took about 1–2 h.
The interviews with professionals were held in their ofﬁces and took 1–2.5 h.
When the health care professionals were interviewed, they were still treating most
of the patients; ﬁve patients had already died. The interview topics were based on
the disease course of the patients who were included and being observed, and
addressed the view of the professional. Furthermore, the professionals were invited
to talk about other (possibly contrasting) experiences with patients.
Data Analysis
The unit of analysis was the disease course of 13 patients, with information
provided by observations, subsequent interviews with patients, and single interviews
with attending physicians and nurses. Interviews were typed out verbatim and coded
with MAXqda
  software. Recurrent themes were inductively identiﬁed through
constant comparison, and could be tested by the short cyclic process of analysis and
data collection [19]. To increase validity and reliability, the interviewer discussed
transcripts and coding with various people (a qualitative researchers forum, a trainee
medical student, Jeannette Pols and DW) [12].
In addition to technical matters related to the interviews and data interpretation,
the interviewer kept a diary to reﬂect on her own role and opinions. For example,
her initially negative attitude towards continuing chemotherapy until the ﬁnal weeks
of life was challenged when she encountered ideas about living a ‘‘good life’’ and
dying while continuing chemotherapy.
Results
We identiﬁed three characteristics of the treatment course in the routine care of
patients with metastatic colorectal and pancreatic cancer. These characteristics
Health Care Anal (2010) 18:164–174 167
123contribute to the idea that the vocabulary of decision-making is not always sufﬁcient
and adequate to describe the practise of palliative oncology.
Numerous Options
We found that the treatment course of metastatic cancer (with or without
chemotherapy) was characterised by many options. There were different possibili-
ties with regard to the dose, frequency, and number of chemotherapy courses. Apart
from many options while having chemotherapy, there were also many treatment
options while having supportive care alone, like trying out a complementary
treatment. Patient and physician continuously tailored the treatment in many
different ways, based on the patient’s condition, his or her experience with
treatments, the patient’s wishes, and the expected effectiveness of the actual
treatment. In the following excerpt from an interview, the frequency of the
chemotherapy courses is changed. This is just one of many ways in which treatment
can be adapted.
Interviewer: You told me you’re taking a bit more time between chemotherapy
courses?
Patient 8: Yes, this suits me very well, because we went on vacation for 2 weeks
and I did not need to take those pills and everything tasted good again and I
could eat everything I liked. Actually, I hadn’t felt that well before—I felt weak
and very tired.
Interviewer: So do you hope to have a longer interval between courses?
Patient: Yes, for example, one time I can go every 3 weeks and every 4 weeks
another time. I’ll see.
In this case, the planning of a vacation caused the 3-weekly chemotherapy
regimen to be adapted. The patient said she felt much better with this new regimen.
Although a standard regimen existed, together with her physician she came up with
an alternative, alternating regimen of once every three and then once every 4 weeks.
The dose and number of courses as well as the frequency of courses can be adapted
in numerous ways. This shows that the practise of palliative chemotherapy is much
more complex than the choice with a dilemmic character, namely either palliative
chemotherapy or no chemotherapy, that patients might experience. It is more about
how much, how often, and how long.
Options Change
Another remarkable feature of the treatment course was that the nature of the
options changed. In contrast to the idea that options are stable—we encountered
options that did change identity. In the following interview excerpt, the option of
taking a break from chemotherapy gradually changed into stopping completely. The
situation Oncologist 2 is talking about is clearly an example of an option that
changed identity. Somehow, ‘‘tomorrow never came’’.
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ﬁnally did not have a third cycle of chemotherapy. What made him, or both of
you, decide against it?
Oncologist 2: Well, a few things. First of all, he did not have many symptoms
from his cancer. And second, he hardly beneﬁted from his earlier cycles of
chemotherapy. In fact, they did not do a thing. I also told him I did not expect
much. I don’t know whether that was decisive for him. From the beginning, he
very much agreed with the idea of not starting immediately. And at that time he
felt he would start treatment later on. But at a certain moment, this idea had
changed. Maybe because he had thought about it himself, or maybe he had
discussed it with someone else, I don’t know. Although nothing had changed in
his health status, somehow he was sure that he wouldn’t take the third cycle.
In the excerpt, the interviewer is referring to deciding whether or not to restart the
treatment—the pros and cons of this decision would have to be weighed up against
each other. But what we observed was different. Nothing was really decisive. A
break in the treatment might turn into stopping treatment completely, even if no one
made this explicit. Rather than deciding to stop, it just ‘‘happened’’ that the option
of ‘‘taking a break’’ turned into ‘‘not having any more chemotherapy’’.
Another example of a change in the nature of an option was observed in the story
of Oncologist 8. He described a patient who tried out one treatment and then
switched to another one. Instead of weighing up clear treatment options, this
switching to a less toxic treatment turned out to be a way of starting to accept the
end of life.
Oncologist 8 about a patient (not included in our study) with a tumour that was
moderately sensitive to chemotherapy: A patient with a metastatic gastric tumour
started with a CEC course [Capecitabine Epirubicine Cysplatin]. I already had
my doubts, but he wanted it very much so we decided to evaluate his clinical
improvement after one chemotherapy course, after which we would be able to
decide again. Then his health deteriorated, but he was not yet ready for the idea
of stopping the treatment. We then switched to an oral chemotherapy. He ﬁnished
one course and then deteriorated again rapidly. I met him once more and at that
time we decided we couldn’t go on like that.
Interviewer: So that’s part of your treatment too: the feeling you have to do
something?
Oncologist 8: Yes, I thought such a difﬁcult course of treatment was too much, so
we found a compromise with the oral chemotherapy. Although I think I would
have preferred to stop, we were talking about something we both had to agree on.
This was a reasonable solution.
This patient had a gastric tumour with a poor prognosis and he did not respond
well to the ﬁrst type of chemotherapy. However, there were still numerous treatment
options (it was not a question of just ‘‘yes or no’’). In this speciﬁc situation,
however, the option of trying out a less toxic treatment turned out to be a way of
starting to accept the end of life. According to the oncologist, the patient ‘‘was not
yet ready for the idea of stopping the treatment’’. The oral chemotherapy, as an
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patient to ﬁnally stop any treatment aimed at improvement. Treatment options are
not always stable and they may change identity.
No Closure
According to the dictionary deﬁnition, a decision is a resolution and hence a closure
of a process of consideration (option X means no option Y, Z, etc.). However, in our
study the treatment course often involved a continuous process in which the
numerous treatment options remain open and can change identities, and in which
there is frequently no closure at all. Take the example of ‘‘postponing the start of
chemotherapy’’. This may lead to many different activities, such as going on
vacation or trying out some alternative treatment. During these activities, the
question of whether or not to start chemotherapy is not resolved but remains open.
The following excerpt illustrates how numerous options remain.
Patient 10: If hospital X can only offer Gemcitabine [type of chemotherapy],I
don’t need to decide yet. Nor will I decide if they offer experimental chemo—
nothing has been proven about this yet and the toxic qualities are still being
investigated. I don’t want to be used as a guinea pig. So I decided to take a month
off and now I’m looking around to see what else is available. (…) In fact, I
decided I’ll have the tumour measured at the beginning of April. If the tumour has
gotten substantially smaller, I’ll say, don’t make changes to a winning team
[refers to the alternative medicine he is using at the moment]. But I don’t expect
that, so it will probably be best to take the next step at that time and to add
something. Let’s see where it ends up.
During the second interview 2 months later, it emerged that this patient had been
actively involved in his treatment course: he continued to use his homoeopathic
medicines and had also started a hyperthermia treatment abroad, had visited several
allopathic physicians for additional information, and was still not having any
chemotherapy. These activities were not preceded by a ‘‘closing decision’’ at one
moment but continuously emerged and changed. The different treatment options,
including chemotherapy, remained open.
Rather than just starting a treatment, it could be tried out ﬁrst. This option
explicitly implies that the treatment can be stopped. So, taking a treatment does not
mean closing off the possibility of having no chemotherapy. Patient 8 told how she
tried out a treatment regimen. Although the interviewer and patient both spoke of
‘‘decision-making’’, the excerpt illustrates that the character of the treatment course
does not close off all other options, because the possibility of stopping the treatment
is included in her considerations.
Interviewer: Do you have the feeling you decided for yourself, that you weighed
up the speciﬁc advantages and disadvantages connected with continuing another
kind of treatment?
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said, Let’s go for it. If it makes me very sick, I can always stop. I can at least try
it.
Of course, a critical reader could also argue that this quote illustrates that a
decision was made, with ‘deciding’ to start a second cycle of chemotherapy.
However, the excerpt also shows that by speaking in terms of ‘‘trying out’’ a
treatment, almost all options—like continuing, stopping, and changing the
chemotherapy, or the option of switching to another chemotherapy—remain open.
In the treatment course of metastatic cancer, options continue to remain open and
are not closed as is the implicit idea of ‘deciding’ in metastatic cancer.
Discussion and Conclusion
Discussion
This study has shown that the treatment course of metastatic cancer is more erratic
than is easy to describe in straightforward terms used in decision making models.
The main ﬁndings are:
1. There were many treatment options (including chemotherapy or not).
2. These options were not stable entities to be decided upon, but changed identity
over the treatment course.
3. Contrary to the closure (option X means no option Y, Z, etc.) a decision
implies, the treatment course was a continuous process in which options
remained open.
We looked for a metaphor to further clarify the erratic characteristics of the
treatment course we encountered in our analysis. Skiing down a mountain has a
clear ending at the bottom (any treatment goal) and a skiing instructor or guide (the
physician) can accompany you. In off-piste skiing, you have to ﬁnd your way in the
virgin snow. This involves numerous erratic routes that may turn into icy slopes, or
a seemingly rough surface may turn out to be a beautiful descent. These routes can
be adapted continuously. With touring skis you even might climb back up, so that
options remain open. In contrast, decision-based models often look more like
deciding for one out of a number of prepared ski slopes.
Mol, in her recent work on care for diabetes patients, uses another metaphor that
might be useful [15]. She describes the care provided by health care professionals
for patients as a process of trying out, evaluating, and adjusting—in contrast to
weighing up and managing by taking decisions. She introduces the concept of
‘‘calibration’’ to describe what professionals and patients do in diabetes care. We
believe our ﬁndings are quite comparable. However, ‘‘off-piste skiing,’’ or
‘‘calibration’’ intuitively seems to ﬁt better with a long-standing physician-patient
relationship in a chronic care setting (as in Mol’s diabetes care), rather than with
those in our study population, who are facing death. We found no evident
differences in the erratic treatment course of either pancreatic or colorectal cancer.
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course is characterised by many and changeable options that do not result in closure.
Studies about decision-making in cancer therapy show (1) that not all patients
want to participate in the decision-making, [6, 13, 18] and (2) that they highly value
being able to trust their physician [9, 20]. These study results can be better
understood in the light of our ﬁndings. Patients possibly say they do not want to
participate or have the responsibility in decision-making because one-off decision-
making is rarely the central activity. Added to the complexity of the many
changeable options that do not result in closure, trust is possibly the only thing left
for patients.
What are the consequences of our data for patient-physician communication
models? Of course we could say the practise should be corrected by preventing
erratic processes and implementing clear decisions. However, we believe our
ﬁndings reﬂect an essential part of the care for the metastatic cancer patient, and
therefore current communications models should be adapted. We will discuss the
consequences with regard to shared decision making (SDM) which, in our view, is
the preferable existing model because of its critical stance to both paternalism and
extreme reliance on patient autonomy. SDM is usually advocated as a model for
how treatment decisions can—and according to some people, should—be made [2,
3]. This type of decision-making is especially associated with treatments for which
the beneﬁts are not evident and need to be weighed up against (sometimes
considerable) burdens, as is the case in palliative cancer chemotherapy [4, 8, 17].
However, SDM does not reveal anything about the content of decision making,
about what kind of decision can be made. In the care for cancer patients SDM is
often used as a model for deciding to start or forgo chemotherapy.
Conclusion
In this study we have shown that some issues in the treatment course of advanced
cancer stay underexposed in the current elaborations of the SDM model. Our
analysis shows that clear-cut decisions are difﬁcult to pinpoint in the communi-
cation between physician and patients about palliative chemotherapy, and that the
process leading to a treatment trajectory is often more erratic than decision models
allow for. For instance, communication researchers and ethicists should realise that
patients and physicians not only deliberate about values attached to ﬁxed treatment
options but also create new options about which they deliberate.
Our conclusion could be contested by saying that we used a concept of ‘decision’
(one-off and conclusive) that is too narrow, and that every disease trajectory may be
rewritten as a series of small and at least partly revocable decisions. Even off-piste
skiing could be argued to consist of such smaller decisions. However, we believe
that this objection would miss the point. Rewriting a disease course, or an off-piste
ski run, in terms of decisions is only possible in retrospect, not in the act. Therefore,
if it were easily pronounceable, it would be better to speak of shared trajectory
making instead of decision making, STM instead of SDM. Just like off-piste tracks
are made by sliding, not deciding, disease trajectories are made by events, actions,
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SDM.
Our analysis implies a number of ways for improvement of the practise of
metastatic cancer treatment. First, the physician has to provide continuous
information related to the speciﬁc circumstances in time and to the patient’s
changing situation. When the treatment is a trajectory, because the communication
is an ongoing process; the physician needs to be an even better communicator than
in the recent SDM model. At the same time, the erratic character of a trajectory
removes the demand that all relevant information should be given at one time (the
moment of decision-making). To some extent, this would give the physician many
opportunities to communicate.
Second, ﬂexibility in dealing with protocols is warranted because the course of a
trajectory is not given. For example, treatment protocols should not always be
strictly followed. One radiotherapist interviewed put it this way: ‘‘Where a cure is
concerned, a guideline sets obligations—but the more ‘palliative’ it becomes, the
more reasons—which are also medically imperative—you have not to follow the
protocol and to focus on the individual’’. This ﬂexibility conﬂicts with the strict
research protocols of clinical trials, which causes tension for those patients with
metastatic disease who participate in such trials.
Third, vigilance (especially on the part of the physician) about the overall
direction of a particular patient trajectory would seem to be of great value because
treatment goals are not deﬁned beforehand [5]. The patient and the physician may
ﬁnd themselves in unexpected places. For example, in the situation of Patient 10
(who postponed the decision on whether or not to start chemotherapy), the attending
physician also needed to point out the consequences of postponement. If the patient
deteriorates rapidly, it could sometimes be too late for this form of treatment.
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